RecruitingNCT04131036

Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A

Studying Hemophilia A

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Washington Institute for Coagulation
Principal Investigator: Rebecca Kruse-Jarres, MD, MPH, M.D
Washington Institute for Coagulation
Intervention: assessment of joint health and bone density(other)
Enrollment: 40 enrolled
Eligibility: 16 years · MALE
Timeline: 2019 – 2026

Study locations (4)

Orthopedic Hemophilia Treatment Center, Los Angeles, California, United States
Hemophilia and Thrombosis Treatment Center, University of California, San Diego, San Diego, California, United States
The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Washington Center for Bleeding Disorders at Washington Institute for Coagulation, Seattle, Washington, United States

Collaborators

Genentech, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04131036 on ClinicalTrials.gov

Other trials for Hemophilia A

Additional recruiting or active studies for the same condition.

See all trials for Hemophilia A →

← Back to all trials